Cadth breakfast session guidelines (april 12 2016) full slide deck_final
-
Upload
cadth-acmts -
Category
Healthcare
-
view
142 -
download
0
Transcript of Cadth breakfast session guidelines (april 12 2016) full slide deck_final
Updating the Guidelines for the Economic Evaluation of Health Technologies: Canada
Welcome
• Project update
• Feedback from stakeholders
• Supporting work
• How to stay informed
• What’s next
2
Updating the Guidelines
• Who?• What?• Why?• How?• When?
3
4
Who?
• CADTH• Health Economics Working Group• Health Economic researchers
5
Health Economics Working Group• Karen M. Lee (Chair), CADTH; University of Ottawa• Dr. Stirling Bryan, University of British Columbia;
Vancouver Coastal Health Research Institute• Dr. Doug Coyle, University of Ottawa; Brunel University• Dr. Murray Krahn, University of Toronto; Toronto Health
Economics and Technology Assessment Collaborative; University Health Network
• Dr. Carlo Marra, Memorial University• Dr. Chris McCabe, University of Alberta, University
of Leeds
6
7
• Developments in methodologies in 2006
• Areas identified where clarity needed
• Assist “doers” and “users” of economic evaluations with the production of credible and standardized economic information
• Provide a set of standards for the conduct and reporting of economic evaluations
Why?
8
9
10
Purpose
• To determine areas of most interest to stakeholders• To ensure all areas of interest have been identified
• Survey period: December 2015 to January 2016
Survey
• Four main questions• Seeking feedback on:
• What respondents feel is useful• What should/should not be updated• Other items of interest to stakeholders
11
Survey ResponsesTotal of 20 responses
Academics (5)
Pharmaceutical industry/Consultants
(8)
HTA orga-nizations
(3)
Decision makers (2)
Patient groups (2)
12
What do you find most useful?
• Clear and definitive guidance • Appropriately structured • Comprehensive in scope
13
14
What topics should be updated? • Responses ranged from general topic areas to be
considered to specific items for consideration within topics
• Effectiveness• Discounting • Measurement and Valuation of Health• Resource Use and Costs• Equity• Generalizability• Uncertainty
All areas should be open to review
What topics should be clarified?
• Types of Evaluations• Perspective• Comparators
15
Additional Suggestions
• Guidance on reviews of drugs for rare diseases• Incorporate oncology guidance within the updated 4th
edition• Update Guidelines more frequently• Educate lay community on concepts of health economic
evaluation
16
Linking with the Update
• Aligned with CADTH thoughts for update • Validation of topics where more effort has been spent
17
18
Network Meta-
analysis
Why Network Meta-Analysis?
• Network Meta-analysis (NMA) is an evolving area of research
• Details on its applicability and use in economic evaluations are limited
• Guidance required on the topic to help inform Guideline update
20
What is Network Meta-Analysis?
• A key element of evidence-based health care evaluation is to assess the effectiveness and cost-effectiveness of all relevant alternative interventions based on the available evidence
• Evidence synthesis technique for summarising the effectiveness data by quantitatively combining the data in order to obtain overall pooled estimates of effectiveness
21
What Distinguishes Network Meta-Analysis from Meta-Analysis?
Overall Pooled Estimates of Effectiveness
A vs. B
Meta-analysis (MA)Network Meta-analysis (NMA)
A vs. B
A vs. B
A vs. C
B vs. C
A vs. B
Allows for the simultaneous estimation of comparative effectiveness of multiple interventions using studies that individually may not compare all interventions
Allows for the estimation of comparative effectiveness of two interventions using studies that individually compare both interventions
22
How to Incorporate Network Meta-Analysis into Economic Evaluations?
• The report focuses on how to use the results from NMA to inform parameters in an economic evaluation:
STEP 1: Define network of studies
STEP 2: Estimate relative treatment effects
STEP 3: Estimate absolute effects (e.g., probabilities)
STEP 4: Evaluate the decision problem based on the estimated effects and the associated uncertainty
23
Other Topics • Using estimates from published NMAs to inform clinical
parameters in an economic evaluation
• Using NMA to synthesise information on adverse events or where data are sparse
• Advanced and emerging topics related to NMA and its use in economic evaluation
• Case studies illustrating the application of standard and advanced NMA methodology to inform clinical parameters
24
Informing the Guidelines
Modelling
Effectiveness
Uncertainty
Discounting: Perspective on Social Choice
Welfarist Extra Welfarist
Social Decision Maker
27
Discounting: Constrained or Unconstrained budgets
Constrained Budget
Opportunity costs fall on health care
budget
Unconstrained Budget
Opportunity costs fall other
budgets or taxpayer
28
Choice of Discount rate: Welfarist/ Extra-welfarist
Constrained Budget
Discount Costs ($s) at: SRTP for consumption minus the expected growth rate in the consumption value of health plus expected growth rate in the cost effectiveness threshold
Discount Health at: SRTP for Consumption minus expected growth rate in the consumption value of health
29
Choice of Discount rate: Social Decision Maker
Constrained Budget
Discount costs at: the real rate interest faced by the higher authority which finances the health system
Discount Health at: the real rate of interest faced by the higher authority minus the expected growth rate of the cost effectiveness threshold
30
Social Rate of Time PreferenceRamsey Equation for the Social Rate of Time Preference
μg + L + δ
μg = Elasticity of utility of consumption*marginal consumptionL = Catastrophic riskδ = Pure time preference
μg = 2.65% (Evans et al, IFS, 2005)L = < 1% (Stern et al, 2006)δ = 0%
2.65%<SRTP<2.75%
31
3 Y 5 Y 7 Y 10 Y 20 Y 30 Y
-1.000
-0.500
0.000
0.500
1.000
1.500
2.000
Dec 2014 Real Yield Curve (BofC Target)
ONPQNSBCABSKPEINFLNBMN
Yiel
d %
Discounting: Real rate of interest
32
Choice of Discount rate: Social Decision Maker
Constrained Budget
Discount costs at: the real rate interest faced by the higher authority which finances the health system
Discount Health at: the real rate of interest faced by the higher authority minus the expected growth rate of the cost effectiveness threshold
33
Discounting: Growth in the cost effectiveness threshold & Lambda
Budget Efficiency Demand Lambda
= =
= =
= == == == =
Discounting Issues
• What is the relevant perspective on Social Choice?
• Is the budget constrained or unconstrained?
• Will the cost effectiveness threshold increase, decrease or remain stable over time?
35
Discounting: Real rate of interest
36
How to stay informed?
• Website updateso Posting of commissioned reportso Alerts for feedback
• Subscribe to CADTH health economic updates
37
What’s next?
• Technical Peer Review Summer 2016
• Stakeholder Review Fall 2016
• Finalize 4th Edition of the Guidelines Winter 2017
Stay tuned for planned workshops & information sessions
39
40
Subscribe to ourHealth Economics Update
42